Show simple item record

Modelling cost-effectiveness of a biomarker-based approach to neoadjuvant chemotherapy for muscle-invasive bladder cancer

dc.contributor.authorWoldu, Solomon L.
dc.contributor.authorMilowsky, Matthew I.
dc.contributor.authorSanli, Oner
dc.contributor.authorBlack, Peter
dc.contributor.authorLotan, Yair
dc.date.accessioned2021-03-05T17:23:08Z
dc.date.available2021-03-05T17:23:08Z
dc.date.issued2018
dc.identifier.citationLotan Y., Woldu S. L. , Sanli O., Black P., Milowsky M. I. , "Modelling cost-effectiveness of a biomarker-based approach to neoadjuvant chemotherapy for muscle-invasive bladder cancer", BJU INTERNATIONAL, cilt.122, ss.434-440, 2018
dc.identifier.issn1464-4096
dc.identifier.otherav_c5524d84-b199-4a52-8057-b327c5eee193
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/130837
dc.identifier.urihttps://doi.org/10.1111/bju.14220
dc.description.abstractObjectivesTo model the cost-effectiveness of a biomarker-based approach to select patients for neoadjuvant chemotherapy (NAC) before radical cystectomy (RC) in muscle-invasive bladder cancer (MIBC).
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectNefroloji
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectÜROLOJİ VE NEFROLOJİ
dc.titleModelling cost-effectiveness of a biomarker-based approach to neoadjuvant chemotherapy for muscle-invasive bladder cancer
dc.typeMakale
dc.relation.journalBJU INTERNATIONAL
dc.contributor.departmentUniversity of Texas System , ,
dc.identifier.volume122
dc.identifier.issue3
dc.identifier.startpage434
dc.identifier.endpage440
dc.contributor.firstauthorID256280


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record